monoclonal | ADC Review

EORTC/GIMEA Trial Does Not Show Benefits for Older AML Patients

Results of a randomized phase III trial evaluating the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy provides no benefit in...

Study Shows Combination of Epratuzumab and Rituximab in Newly Diagnosed Follicular...

Peter Hofland

The combination of epratuzumab, a humanized anti CD-22 monoclonal antibody, and rituximab (Rituxan®/Genentech; MabThera®/Roche), as a front-line therapy of patients with newly diagnosed follicular lymphoma (FL), produced...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From...

Peter Hofland

Earlier this month French pharmaceutical giant Sanofi-aventis acquired an exclusive world-wide license to one of Oxford BioTherapeutics’ internal preclinical antibody programs. Sanofi-aventis intends to...

Tag: monoclonal

EORTC/GIMEA Trial Does Not Show Benefits for Older AML Patients

Study Shows Combination of Epratuzumab and Rituximab in Newly Diagnosed Follicular...

Sanofi-Aventis In-licenses Therapeutic Antibody for the Treatment of Solid Cancers From...

Latest

Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering

Pyxis Oncology Positions Itself at the Forefront of ADC Development with Aquisition of Apexigen

ATG-022, a Claudin 18.2 ADC, Receives Orphan Drug Designations for the Treatment of Gastric...

Peer Review

Automating ADC Manufacturing with Electricity

Advances in the Development of Dual-Drug Antibody Drug Conjugates

Recent Advances in Antibody-drug Conjugates Produced Using Chemical Conjugation Technology